Combination chemotherapy with adriamycin (NSC 123127) and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU; NSC 79037)

L. H. Einhorn, Robert B Livingston, J. A. Gottlieb

Research output: Chapter in Book/Report/Conference proceedingChapter

14 Citations (Scopus)

Abstract

41 patients with various solid tumors were treated with a combination of adriamycin and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU). Adriamycin was given every 3 wk at a dose ranging from 40-75 mg/m2, and CCNU was given every 6 wk at a dose ranging from 65-125 mg/m2. The cases of 33 of the 41 patients were considered evaluable. Three patients had complete responses and 11 had partial (greater than 50%) remissions for a response rate of 34% considering all patients treated, or 42% considering only those with evaluable cases. Responses were noted in patients with cancer of the breast (8 of 13), squamous cell carcinoma of the head and neck (3 of 6), malignant melanoma (1 of 8), undifferentiated carcinoma with unknown primary site (1 of 5), and lymphoma (1 of 4). The combination was well tolerated; its main toxic effects were vomiting, alopecia, and hematologic depression. With this combination there were 2 nadirs of myelosuppression: one occurred on Day 15 and the other occurred on Day 36. Prolonged thrombocytopenia was occasionally seen after multiple doses of CCNU.

Original languageEnglish (US)
Title of host publicationCANCER CHEMOTHER.REP.
Pages437-445
Number of pages9
Volume57
Edition4
StatePublished - 1973
Externally publishedYes

Fingerprint

Lomustine
Combination Drug Therapy
Doxorubicin
Poisons
Alopecia
Thrombocytopenia
Vomiting
Melanoma
Lymphoma
Breast Neoplasms
Carcinoma
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Einhorn, L. H., Livingston, R. B., & Gottlieb, J. A. (1973). Combination chemotherapy with adriamycin (NSC 123127) and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU; NSC 79037). In CANCER CHEMOTHER.REP. (4 ed., Vol. 57, pp. 437-445)

Combination chemotherapy with adriamycin (NSC 123127) and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU; NSC 79037). / Einhorn, L. H.; Livingston, Robert B; Gottlieb, J. A.

CANCER CHEMOTHER.REP.. Vol. 57 4. ed. 1973. p. 437-445.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{23701c62669c414c89ee506a65febb10,
title = "Combination chemotherapy with adriamycin (NSC 123127) and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU; NSC 79037)",
abstract = "41 patients with various solid tumors were treated with a combination of adriamycin and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU). Adriamycin was given every 3 wk at a dose ranging from 40-75 mg/m2, and CCNU was given every 6 wk at a dose ranging from 65-125 mg/m2. The cases of 33 of the 41 patients were considered evaluable. Three patients had complete responses and 11 had partial (greater than 50{\%}) remissions for a response rate of 34{\%} considering all patients treated, or 42{\%} considering only those with evaluable cases. Responses were noted in patients with cancer of the breast (8 of 13), squamous cell carcinoma of the head and neck (3 of 6), malignant melanoma (1 of 8), undifferentiated carcinoma with unknown primary site (1 of 5), and lymphoma (1 of 4). The combination was well tolerated; its main toxic effects were vomiting, alopecia, and hematologic depression. With this combination there were 2 nadirs of myelosuppression: one occurred on Day 15 and the other occurred on Day 36. Prolonged thrombocytopenia was occasionally seen after multiple doses of CCNU.",
author = "Einhorn, {L. H.} and Livingston, {Robert B} and Gottlieb, {J. A.}",
year = "1973",
language = "English (US)",
volume = "57",
pages = "437--445",
booktitle = "CANCER CHEMOTHER.REP.",
edition = "4",

}

TY - CHAP

T1 - Combination chemotherapy with adriamycin (NSC 123127) and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU; NSC 79037)

AU - Einhorn, L. H.

AU - Livingston, Robert B

AU - Gottlieb, J. A.

PY - 1973

Y1 - 1973

N2 - 41 patients with various solid tumors were treated with a combination of adriamycin and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU). Adriamycin was given every 3 wk at a dose ranging from 40-75 mg/m2, and CCNU was given every 6 wk at a dose ranging from 65-125 mg/m2. The cases of 33 of the 41 patients were considered evaluable. Three patients had complete responses and 11 had partial (greater than 50%) remissions for a response rate of 34% considering all patients treated, or 42% considering only those with evaluable cases. Responses were noted in patients with cancer of the breast (8 of 13), squamous cell carcinoma of the head and neck (3 of 6), malignant melanoma (1 of 8), undifferentiated carcinoma with unknown primary site (1 of 5), and lymphoma (1 of 4). The combination was well tolerated; its main toxic effects were vomiting, alopecia, and hematologic depression. With this combination there were 2 nadirs of myelosuppression: one occurred on Day 15 and the other occurred on Day 36. Prolonged thrombocytopenia was occasionally seen after multiple doses of CCNU.

AB - 41 patients with various solid tumors were treated with a combination of adriamycin and 1 (2 chloroethyl) 3 cyclohexyl 1 nitrosourea (CCNU). Adriamycin was given every 3 wk at a dose ranging from 40-75 mg/m2, and CCNU was given every 6 wk at a dose ranging from 65-125 mg/m2. The cases of 33 of the 41 patients were considered evaluable. Three patients had complete responses and 11 had partial (greater than 50%) remissions for a response rate of 34% considering all patients treated, or 42% considering only those with evaluable cases. Responses were noted in patients with cancer of the breast (8 of 13), squamous cell carcinoma of the head and neck (3 of 6), malignant melanoma (1 of 8), undifferentiated carcinoma with unknown primary site (1 of 5), and lymphoma (1 of 4). The combination was well tolerated; its main toxic effects were vomiting, alopecia, and hematologic depression. With this combination there were 2 nadirs of myelosuppression: one occurred on Day 15 and the other occurred on Day 36. Prolonged thrombocytopenia was occasionally seen after multiple doses of CCNU.

UR - http://www.scopus.com/inward/record.url?scp=0015732291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015732291&partnerID=8YFLogxK

M3 - Chapter

VL - 57

SP - 437

EP - 445

BT - CANCER CHEMOTHER.REP.

ER -